Kailera Therapeutics (KLRA) EBITDA Margin (2025 - 2026)
Kailera Therapeutics' EBITDA Margin came in at -1479.34% for Q1 2026, down 261.73 percentage points from -1217.61% a year earlier.
Powered by 
Analysis
Kailera Therapeutics (KLRA) EBITDA Margin (2025 - 2026) Analysis & Trends
Over the trailing twelve months to Mar 31, 2026, Kailera Therapeutics reported EBITDA Margin of -7372.10%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 42.49% |
| 10 | Kailera Therapeutics | 1.72 Bn | -1.16 Bn | - | - |
API Access
Kailera Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KLRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "KLRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KLRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();